Daniel Sanchez, PA
Payments from drug & device makers
Across 421 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$962
- Lilly USA, LLC$902
- AbbVie$726
- Pfizer$693
- AstraZeneca$517
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,219100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $1,058 |
| Novo Nordisk | 57 | $962 |
| Lilly USA, LLC | 53 | $902 |
| AbbVie | 56 | $726 |
| Pfizer | 49 | $693 |
| AstraZeneca | 21 | $517 |
| Amgen | 18 | $303 |
| Daiichi Sankyo Inc. | 12 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $221 |
| Exact Sciences | 10 | $190 |
| Supernus Pharmaceuticals, Inc. | 6 | $183 |
| Merck | 8 | $180 |
| Johnson & Johnson | 7 | $141 |
| Bayer | 9 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Abbott | 5 | $81 |
| Upsher-smith Laboratories LLC | 3 | $73 |
| Novartis | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Grifols USA, LLC | 1 | $24 |
| Inari Medical, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,231 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $112,277 |
| EliquisApixaban | 45 | $54,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $38,763 |
| JardianceEmpagliflozin | 21 | $30,566 |
| MounjaroTirzepatide | 23 | $29,219 |
| XareltoRivaroxaban | 43 | $25,659 |
| JanuviaSitagliptin Phosphate | 20 | $22,653 |
| TrulicityDulaglutide | 15 | $19,677 |
| FarxigaDapagliflozin Propanediol | 14 | $11,820 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,089 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,494 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $6,061 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $5,296 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $4,267 |
| Rosuvastatin Calcium | 214 | $3,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $962 | $112,27788 claims |
| PfizerEliquis | $693 | $54,45745 claims |
| Lilly USA, LLCMounjaro, Trulicity | $902 | $48,89638 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,058 | $47,85356 claims |
| Boehringer IngelheimJardiance | $16 | $30,56621 claims |
| Johnson & JohnsonXarelto | $141 | $25,65943 claims |
| MerckJanuvia | $180 | $22,65320 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $517 | $20,31428 claims |
| AbbVieSynthroid | $726 | $1,07421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Irwin
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.